UBS slammed by Facebook IPO losses

Arnd Wiegmann / REUTERS

People walk behind the logo of Swiss bank UBS in Zurich.

By Roland Jones, NBC News

UBS said Tuesday its earnings in the second quarter were more than halved because of losses from the botched Facebook public stock offering in mid-May.

The Swiss bank said it plans to take legal action against the Nasdaq stock market, which handled the social network?s IPO.

UBS said its net profit in the quarter fell to 425 million Swiss francs, or $434 million, with $357 million in losses coming from?what UBS called ?the gross mishandling? of the Facebook IPO by the Nasdaq Stock Market.

The Nasdaq exposed UBS, as a market maker for the much-anticipated IPO, to ?far more shares than our clients had ordered,? by filling trading orders multiple times, the bank said.

?As a market maker in one of the largest IPOs in U.S. history, we received significant orders from clients, including clients of our wealth management businesses,? UBS said.

?We will take appropriate legal action against Nasdaq to address its gross mishandling of the offering and its substantial failures to perform its duties,? UBS added. ?Although as in all such matters there can be no assurance as to the amount of any recovery we may obtain, we intend to pursue compensation for the full extent of our losses.?

The quarterly losses at UBS are far higher than the $62 million the Nasdaq has set aside to offer as compensation to clients affected by the problems with Facebook?s initial public offering in May.

Facebook?s stock offering was marred by trading glitches and has triggered several lawsuits. The company?s share price has since dropped almost 40 percent from its initial price of $38.

UBS said its quarterly loss was also due to ?challenging conditions marked by increased volatility and greater client caution.? UBS had reported a profit in the same period one year ago.

Click here to check shares of UBS.

Source: http://marketday.nbcnews.com/_news/2012/07/31/13050085-ubs-slammed-by-facebook-ipo-losses?lite

best picture nominees 2012 academy awards 2012 albert nobbs a star is born oscar nominees

Information Regarding Your Personal Development ?

Because stress is a fact today, lots of people are switching to self improvement in order to raise contentment and accomplish private targets. Self improvement should assist somebody fully grasp who they really are and the way to become a greater man or woman. This short article features ways to for your self improvement.

If you suffer from stress and anxiety or anxiety and need to try to relax oneself, ensure you are receiving ample proteins. Most foods that have proteins inside them may help relax your neural system and set you relaxed. Try out food products like salmon, white colored fish, and turkey because they are good alternatives.

Be solutions concentrated. The two main kinds of individuals worldwide: the ones that continuously chuck up troubles without having supplying options and those that talk the difficulties accessible and provide solutions. The latter is who you want to be. Frontrunners are remedies-focused. They view the issues just and also the past, but they don?t cease there. They take the time to produce approaches around the problems.

By taking a remain, transform it into a warranted stand up. You have an burden to you to ultimately obviously determine your thinking, comprehend your values and make with them. Having a get up on any stage or issue has no benefit when you are not devoted and informed in your place. Affirming your belief program in will add knowledge for your posture with out.

One particular important part of self improvement is finding out how to efficiently control your time and effort. Robust time management skills can help you reach your goals more rapidly to get a greater portion of what you need out from existence. Not only that, but managing your time wisely is effective in reducing your entire levels of stress simply by making daily life far less frantic and hurried.

Possessing sincerity as well as a clear conscience could keep on your own-esteem up and self-esteem is crucial to self improvement! Usually do not scrimp, make excuses or give yourself other reasons to feel like you will be not supplying daily life the best energy. Those little things will add up to a weight that will pressure you with a sense of guilt and quit your ability to succeed old in its monitors, along with keeping you against acquiring a very good night sleeping.

Develop a personal development want to get the best from your time and effort determination. Attempting personal development with out a detailed strategy into position with your desired goals and activities typically warranties too little good results since it is tough to continue to be focused on a number of areas of development without an organized program.

In terms of aiding yourself you need to make an attempt to absorb each of the info you might have just figured out and find out the best way to use it appropriately. The true secret to self help is always to discover around you are able to and making use of that details to the best of your skill, only then are you able to wish to aid oneself.

wordpress blog post

Source: http://all-articles-directory.com/information-regarding-your-personal-development/

obamacare Nexus 7 euro 2012 dominion power Colorado Springs pga tour Nora Ephron

Cancer journal pulls deeply flawed meeting abstract on breast surgery

The European Journal of Surgical Oncology has retracted a meeting abstract that evidently was never meant to be.

The study, by researchers at Queen Elizabeth Hospital and Good Hope Hospital, both in Birmingham, England, was to be presented at this year?s annual meeting of the Association of Breast Surgery and purported to compare rates of patient satisfaction among women who underwent two kinds of breast reconstruction, TRAM ? transverse rectus abdominis myocutaneous? ? flap and DIEP (short for deep inferior epigastric perforators) flap.

But according to the notice:

This conference abstract has been retracted at the request of the authors. The research presented in the abstract was undertaken by the authors as a service review and subsequently submitted for presentation as a poster at the Association of Breast Surgery Conference, which took place on the 21st and 22nd May 2012. The authors accepted to present the poster at the Conference, but subsequently withdrew it. However, the abstract had already been published in the European Journal of Surgical Oncology, together with other abstracts from the conference.

The study did not receive ethical approval, and there is disagreement as to whether ethical approval was required. In addition, some patients included in the study were treated by a breast cancer surgeon currently under investigation for using a surgical technique not deemed to be best practice, which may have affected the results. The authors have therefore requested the retraction of this conference abstract and apologise to the readers of the European Journal of Surgical Oncology.

We think the surgeon under investigation might be Ian Paterson, whose patients are being studied for signs that the technique he used might put them at greater risk for metastasis, according to an undated NHS press release. Those surgeries took place at another Birmingham hospital. The release, which refers to a 2007 review, stated that:

The technique involved performing the mastectomy and leaving behind a small amount of residual breast tissue to assist in providing an improved cleavage for the patient. The Trust understands that this procedure was being carried out in good faith, believing it to be appropriate for patients, to achieve removal of the carcinoma, but with a better cosmetic result than a traditional mastectomy. This procedure was not performed on all patients undergoing mastectomy.

The review highlighted that this was not a usual procedure and the appropriate guidelines had not been followed to introduce this new technique. This Trust?s position, after careful consideration, was that the technique was not an approach considered appropriate going forward, and the method was therefore stopped.

We?ve tried to reach the editor of the journal for comment, and will update with anything we hear back.

Hat tip: Clare Francis

Like this:

Be the first to like this.

Source: http://retractionwatch.wordpress.com/2012/07/31/cancer-journal-pulls-deeply-flawed-meeting-abstract-on-breast-surgery/

elon musk al sharpton fox mole manson bubba watson recent earthquakes lollapalooza

Europe and US richly reward Israel for pariah status WORLD NEWS ...

News_World news_News_latest news_WNT+News_Worldnewstomorrow_worlnewstomottow.com

WORLD NEWS TOMORROW ? Israel has barely put a foot right with the international community since its attack on Gaza more than three years ago provoked global revulsion.

The right-wing government of Benjamin Netanyahu has serially defied and insulted foreign leaders, including US President Barack Obama; given the settlers virtual free rein; blocked peace talks with the Palestinians; intimidated and marginalised human rights groups, UN agencies and even the Israeli courts; and fuelled a popular wave of Jewish ethnic and religious chauvinism against the country?s Palestinian minority, foreign workers and asylum seekers.

No wonder, then, that in poll after poll Israel ranks as one of the countries with the most negative influence on international affairs.

And yet, the lower Israel sinks in public estimation, the more generous western leaders are in handing out aid and special favours to their wayward ally. The past few days have been particularly shameless.

It was revealed last week that the European Union had approved a massive upgrade in Israel?s special trading status, strengthening economic ties in dozens of different fields. The decision was a reversal of a freeze imposed in the wake of the Gaza attack of winter 2008.

Amnesty International pointed out that the EU was violating its own commitments in the European Neighbourhood Policy, which requires that, as a preferred trading partner, Israel respect international human rights, democratic values and its humanitarian obligations.

Equally troubling, the EU is apparently preparing to upend what had looked like an emerging consensus in favor of banning settlement products ? the only meaningful punishment the EU has threatened to inflict on Israel.

With some irony, Europe?s turnabout was revealed the same day that Israel announced it was planning to destroy eight villages in the West Bank, expelling their 1,500 Palestinian inhabitants, to make way for a military firing zone. Four more villages are also under threat.

The villagers? expulsion was further confirmation that Israel is conducting a ?forced transfer? of Palestinians, as recent EU reports have warned, from the nearly two-thirds of the West Bank under its control.

Europe?s only real leverage over Israel is economic: business between the two already accounts for about 60 per cent of Israeli trade, worth nearly 30 billion euros. But rather than penalising Israel for repeatedly stomping over the flimsiest prospects for a two-state solution, the EU is handsomely rewarding it.

It is not alone. The United States is also showering economic benefits and military goodies on Israel, in addition to the billions of dollars in aid it hands over every year.

In the past few days alone, President Obama signed a new law greatly expanding military cooperation with Israel and awarded $70 million ? on top of an existing $210 million donation ? for it to develop the Iron Dome missile defence system; the Pentagon arm-twisted Lockheed Martin into collaborating with Israeli firms in revamping the new F-35 fighter jet; and Congress approved a four-year extension of US loan guarantees to make it cheaper for Israel to borrow money on the international markets.

Meanwhile, Obama?s rival for the presidency, Mitt Romney, has criticized Obama for being too miserly towards Israel. As he stood shoulder to shoulder with Netanyahu in Jerusalem on Sunday, Romney issued a press release suggesting that his administration would spend even more US taxpayers? dollars on Israel?s missile defence system.

All this munificence is coming from the two dominant parties to the Quartet ? the international group comprising the US, the EU, the United Nations and Russia. The Quartet?s role is to champion the very two-state solution Israel is striving so strenuously to destroy.

In a further irony, the World Bank issued last week its latest report on the state of the Palestinian economy, concluding that its situation was so dire the Palestinian government-in-waiting, the Palestinian Authority, could not be considered ready for independent statehood. The report noted that the Palestinians were heavily reliant on foreign donors and that local private businesses, agriculture and manufacturing were all in decline.

With feigned obtuseness, the World Bank recommended that the PA increase exports to foreign markets, glossing over the biggest impediment to such trade: the severe restrictions imposed by Israel on the movement of people and goods into and out of Palestinian territory.

As the Quartet has grown ever more silent in the face of Israeli transgressions, US politicians have stepped in with cynical manoeuvres to shore up Israel?s intransigence and destroy any hopes of a peaceful solution.

Last week, for example, US lawmakers were reported to have put their names to a congressional resolution recognizing the recent report of Israel?s controversial Levy Committee. The report concluded that Israel was not occupying the West Bank and that consequently the settlements there are legal.

The topsy-turvy character of international diplomacy was acknowledged this month by a recently retired British ambassador to the Middle East. Tom Philips, who served in Israel and Saudi Arabia, writes in the latest edition of Prospect magazine that Europe and the US need to use ?big carrots and big sticks? if there is to be any hope of reviving the peace process.

But Mr Philips believes the US is ?genetically indisposed? to forcing change on Israel. He proposes instead choking off donor money to the PA so as ?to put the full weight of the occupation on Israel, a burden I do not think they would be able to endure?.

In another of the rich ironies of the Israeli-Palestinian conflict, it now seems even some diplomats are concluding that the Palestinians will be best served by destroying the fledgling government that was supposed to be the harbinger of their independence.

The real obstacles to peace Israel, its occupation and western complicity might then be laid bare for all to see.

Source: http://www.worldnewstomorrow.com/?p=2268

j r martinez long island serial killer wizard of oz jeff green saturday night live aortic aneurysm minnesota timberwolves

Israel's Can-Fite sees positive data for psoriasis drug

TEL AVIV (Reuters) - Can-Fite BioPharma expects to publish positive data at the end of the third quarter regarding the safety and efficacy of its CF101 drug under development for the treatment of psoriasis, the Israeli company's acting CEO said on Wednesday.

CF101, a small molecule oral drug, is in advanced clinical development for the treatment of autoimmune inflammatory diseases such as psoriasis, which affects the skin, and rheumatoid arthritis.

Can-Fite acting CEO and founder Pnina Fishman said the company was conducting a Phase II/III clinical study involving 300 patients in the United States, Europe and Israel.

"We are going to have the interim analysis clinical data towards the end of the third quarter," Fishman told Reuters. "The data is positive ... in terms of safety and efficacy."

Shares in Can-Fite were up 3.8 percent in midday Tel Aviv trade after the clinical trial's investigators presented their findings to investors.

The most effective treatments for psoriasis on the market are biological drugs focused on blocking the inflammatory factor in the body that causes the disease.

Though the drugs are effective, patients may suffer from adverse events that can cause inflammatory conditions as well as depression and sepsis, Fishman said. The cost of treatment per patient is about $20,000 a year and over time patients can stop responding to the drugs.

"There is a need for another type of drug that won't be so expensive and will not induce adverse events," Fishman said.

CF101 is administered as a tablet twice daily while the biological drugs must be administered intravenously.

"We will position it in the market so that the margin of profit will be high for the company but the cost will be much, much lower than for the biological drugs," Fishman said.

Can-Fite will need to conduct a Phase III study in addition to the Phase II/III study underway to obtain approval from the U.S. Food and Drug Administration. Fishman estimated it would take three to four years to register the drug.

About 2 percent of the world's population suffers from psoriasis and the market for treatment of the disease is valued at $3.6 billion a year worldwide. This is estimated to grow to $8.5 billion by 2017.

Can-Fite has licensed CF101 for the treatment of autoimmune diseases to Seikagaku Corp in Japan and for rheumatoid arthritis to Kwang Dong in South Korea. Can-Fite so far has received $8.5 million in upfront payments.

"There never will be a cure for psoriasis but we would like to turn it into a disease where the clinical manifestations will be minimal," Fishman said.

(Reporting by Tova Cohen; Editing by Helen Massy-Beresford)

Source: http://news.yahoo.com/israels-fite-sees-positive-data-psoriasis-drug-093926576--finance.html

esophageal cancer marfan syndrome marfan syndrome britney spears engaged craig smith craig smith eat to live

USC picks up Penn State RB Silas Redd

FILE - This Oct. 29, 2011 file photo shows Penn State running back Silas Redd (25) rushing for 14-yards past Illinois defensive lineman Whitney Mercilus (85) during the first quarter of an NCAA college football game in State College, Pa. A pep band and more than 1,000 fans bearing signs and shouting their support for Penn State football turned out Tuesday morning, July 31, 2012 to greet players gathering for offseason workouts. The Jerry Sandusky sex abuse scandal could cost Penn State current players, most notably Redd, who visited Southern California during the weekend and didn't attend Tuesday's workout. (AP Photo/Gene J. Puskar, File)

FILE - This Oct. 29, 2011 file photo shows Penn State running back Silas Redd (25) rushing for 14-yards past Illinois defensive lineman Whitney Mercilus (85) during the first quarter of an NCAA college football game in State College, Pa. A pep band and more than 1,000 fans bearing signs and shouting their support for Penn State football turned out Tuesday morning, July 31, 2012 to greet players gathering for offseason workouts. The Jerry Sandusky sex abuse scandal could cost Penn State current players, most notably Redd, who visited Southern California during the weekend and didn't attend Tuesday's workout. (AP Photo/Gene J. Puskar, File)

FILE - This July 13, 2012 file photo shows Penn State running back Silas Redd taking a break during a competition against the defense during the 10th annual Uplifting Athletes Lift for Life on the main campus of Penn State University in State College, Pa. A pep band and more than 1,000 fans bearing signs and shouting their support for Penn State football turned out Tuesday morning, July 31, 2012 to greet players gathering for offseason workouts. The Jerry Sandusky sex abuse scandal could cost Penn State current players, most notably Redd, who visited Southern California during the weekend and didn't attend Tuesday's workout. (AP Photo/Gene J. Puskar, File)

FILE - This Sept. 3, 2011 file photo shows Penn State running back Silas Redd (25) reacting after scoring a touchdown against Indiana State during the first quarter of an NCAA college football game in State College, Pa. A pep band and more than 1,000 fans bearing signs and shouting their support for Penn State football turned out Tuesday morning, July 31, 2012 to greet players gathering for offseason workouts. The Jerry Sandusky sex abuse scandal could cost Penn State current players, most notably Redd, who visited Southern California during the weekend and didn't attend Tuesday's workout. (AP Photo/Gene J. Puskar, File)

Southern California coach Lane Kiffin takes questions at the Pac-12 NCAA college football media day in Los Angeles, Tuesday, July 24, 2012. (AP Photo/Damian Dovarganes)

Penn State fans cheer during a pep rally of supporters for the Nittany Lions football team on their way to a morning workout outside the Lasch Football building on the Penn State main campus in State College, Pa., Tuesday, July 31, 2012. (AP Photo/Centre Daily Times, Christopher Weddle) MANDATORY CREDIT; MAGS OUT

(AP) ? Penn State's loss could turn into a big gain on the ground for Southern California.

Star tailback Silas Redd bolted Happy Valley to join the Trojans in a season of great expectations in Los Angeles. A 1,200-yard rusher, Redd will join heralded quarterback Matt Barkley on a team already favored to win the Pac-12 and return to the Rose Bowl.

It's a perk that Redd wouldn't have enjoyed at Penn State with the program burdened by stiff NCAA sanctions because of the Jerry Sandusky child sex abuse scandal. Among the penalties was a four-year postseason ban, as well as a scholarship reduction.

The NCAA also allowed players to seek new schools to play immediately this season, so long as they left by the start of Penn State training camp on Monday.

Since the sanctions were imposed last week, Nittany Lions coach Bill O'Brien has been trying to keep the team intact by stressing academics, family and the prospect of playing seven home games a year in front of a crowd of 108,000 strong at Beaver Stadium.

For the most part, it seems to have worked ? even though Redd's departure will be a serious blow to an offense being reconfigured by O'Brien, the former coordinator of the New England Patriots' high-powered attack.

Counting Redd, three players have left Penn State since the NCAA imposed its landmark sanctions on July 23. A fourth player, third-string quarterback Rob Bolden, was removed from the roster this week but had been granted permission to talk to other schools before the sanctions.

Otherwise, O'Brien hasn't lost any other starters or top backups so far. He had also said last week at Big Ten media days that more than 50 players had indicated they would stay. Six 2013 recruits have also reaffirmed their verbal commitments.

Penn State athletic director Dave Joyner wished Redd and the other transfers well. "I think that certainly we understand and it's within their purview," Joyner said in an interview Tuesday night with The Associated Press at an evening football function.

He added the low number of transfers was "a great testament to Bill O'Brien, and the kind of person he is, the kind of coach he is and the kind of players these are overall.

"This team has a lot of unity."

But it won't have Redd. Sophomore Bill Belton, a converted wideout, is next on the Penn State depth chart, and that could prove to be a roadblock as O'Brien tries to transform the offense on the fly.

Out west, Redd joins a team that finished 10-2 and No. 6 in the final AP poll last season despite its own NCAA sanctions ? bowl ineligibility and a smaller roster. After Barkley and safety T.J. McDonald decided in December to return for their senior years, USC signed a top-flight recruiting class led by elite quarterback prospect Max Browne.

Redd could make the Trojans even better.

"We welcome Silas Redd to the Trojan Family," USC athletic director Pat Haden said in a statement. "He is an outstanding student and athlete."

USC had been sanctioned for rules violations committed during the 2004 and '05 seasons.

"At USC, we've seen both sides of this issue, having lost a number of players to transfer due to our NCAA sanctions in 2010. But Lane Kiffin and his coaches would not be doing their job if they did not try to improve our team every single day," Haden said. "There is a specific need here for a player like Silas Redd, so Lane and our coaches recruited him within the guidelines set up in this instance by the NCAA."

An early-morning rally and last-minute social media campaign couldn't keep Redd from leaving Penn State. He took a weekend visit to USC before delivering the news to Nittany Lions coaches at the team headquarters ? about 12 hours after Tuesday's "Rise and Rally" community event to rouse the players at morning workouts.

Penn State said later Tuesday that tight end Kevin Haplea was also no longer with the team. It was unclear where the junior, who started one game last year, was headed. Backup safety Tim Buckley, a former walk-on, was the first player to leave Penn State in the wake of the sanctions. He joined North Carolina State this week.

And then, there is the case of Bolden, the former starting quarterback, who pondered leaving last year, as well. LSU has shown an interest in Bolden, yet he has not chosen a new destination.

Most players interviewed after the rally and voluntary workout said they hoped Redd and others would stick around, but would honor their decisions regardless.

"Each player came here for different reasons and with different objectives," tight end Garry Gilliam said. "When it comes down to it, I'd like them to stay, but if they don't, I'll respect their decisions."

Linebacker Khairi Fortt ? like Redd, a junior from Connecticut ? has considered Cal, Florida State and Kansas, his father, Guy confirmed in an email to The Associated Press. The Stamford Advocate first reported details of Fortt's recruitment.

The younger Fortt, a top reserve for Penn State, liked his visit to Cal but loves his Nittany Lions coaches, his father said. His decision could come Wednesday.

The rally was evidence of the Penn State community's resolve to stand behind the Nittany Lions that remain. With the pep band playing, at least 2,500 blue-and-white backers, alumni and local business owners cheered outside the football building Tuesday in support of the players caught in the middle of one of the worst episodes ever in college athletics.

Fans lined the sidewalks to slap high-fives and shake hands with the Nittany Lions as they snaked their way to the workout. The scene resembled the team entrance to home games at Beaver Stadium on fall Saturdays.

Inspirational quotes from Winston Churchill, Thomas Paine and Vince Lombardi were posted in the windows of the building. "It isn't whether you get knocked down. It's whether you get back up," read one quote attributed to Lombardi, the Hall of Fame NFL coach.

"It was so cool. I couldn't believe how loud it was," fullback Michael Zordich said. "This just goes to show why we're still here and why we're going to fight this thing through."

Former player Keith Conlin, a local businessman and online radio show host who helped organize the event said he wanted current team members "to know that we have their backs."

"These kids, they've been fighting an uphill battle for eight months, and it's nothing that they did," he said. "We're not going to leave them and run away."

Most downtown businesses are displaying "Proud to Support Penn State Football" signs on windows. Some stores have started selling shirts with the slogan "Billieve," playing off of O'Brien's first name.

After much deliberation, Redd will not be a part of this revival.

Instead, he's going to chase a title with the Trojans.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/347875155d53465d95cec892aeb06419/Article_2012-08-01-Penn%20State-Players/id-6e5a82779bc949479a5f1273b4b9ba9a

pink slime eagle cam us soccer trayvon martin case affordable care act the line bobby brown arrested

Can Bacteria Fight Brain Cancer

News | Health

The thinking behind an approach that has caused trouble in California.


brain-tumor surgery Infections occurring after brain-tumor surgery may cause cancer regression. Image: Doctor Stock/Getty

By Monya Baker of Nature magazine

Last week, the Sacramento Bee reported that two neurosurgeons at the University of California, Davis, had been banned from research on humans after deliberately infecting three terminally ill cancer patients with pathogenic bacteria in an attempt to treat them. All three died, two showing complications from the infection. Nature explores what happened and the science behind it.

Who authorized the researchers to infect the patients?
All three patients consented to infection. However, anyone testing experimental drugs in the United States requires approval from their university?s Institutional Review Board (IRB) and oversight by the country's Food and Drug Administration (FDA), both of which review evidence for safety and efficacy. Neurosurgeons Paul Muizelaar and Rudolph Schrot at the University of California (UC), Davis, did not obtain this approval; they say they did not think it was required. Harris Lewin, the vice-chancellor of research at UC Davis, wrote a letter to the FDA describing what had occurred as ?serious and continuing noncompliance?.

In 2008, working under instructions from Muizelaar, Schrot asked the FDA about the possibility of deliberately infecting a postoperative wound in a particular patient with glioblastoma with the bacterium Enterobacter aerogenes. He was told that animal studies were needed first. Muizelaar did not infect that patient, but arranged for a graduate student to begin tests in rats. Although bacteria were purchased as research materials not to be used in humans, they were eventually used in three other patients with glioblastoma.

The first of those asked Muizelaar about infection in 2010, and Schrot contacted the director of UC Davis?s IRB asking permission to perform what Lewin?s letter describes as a ?one-time procedure? not intended as research. The director concluded that this procedure could be classed as ?innovative care? that did not require approval by the FDA or IRB, but that subsequent work should be reviewed. Schrot and Muizelaar went on to treat two further patients and were seeking approval from an ad hoc ethics committee (not the IRB or FDA) to treat five more when the IRB director told the neurosurgeons to cease and desist, and began an internal investigation.

How is brain cancer usually treated?
Glioblastoma is an aggressive brain cancer and is usually treated with surgery, as well as with radiation and chemotherapy. However, the cancer almost always recurs after surgery. Half of patients die within 15 months of diagnosis; fewer than one in twenty lives longer than five years.

Why might an infection fight cancer?
There are isolated reports of patients with various types of cancer successfully fighting off an infection only to find that the cancer has also disappeared. Presumably, the infection spurs white blood cells to attack both pathogens and malignant cells. In 1999, researchers at the University of Mississippi Medical Center in Jackson described four case studies in which the regression of malignant brain tumors co-occurred with infection. Enterobacter aerogenes, the same bacterium used at UC Davis, was recovered from microbial cultures taken from three of the patients.

What further studies have been done?
In 2004, a group led by Bert Vogelstein at the Howard Hughes Medical Institute in Maryland introduced cancer cells into mice and rabbits, allowed large tumors to form and then injected the animals with spores of the anaerobic bacterium Clostridium novyi-NT. About one-third of the animals' tumors disappeared, apparently as a result of an immune response.

Source: http://rss.sciam.com/click.phdo?i=96b384f48b6a405483b5102afbaeb500

the duchess spice mike starr ufc 141 fight card gli joseph gordon levitt katy perry russell brand

Restaurant Review: Barbacoa - Ardmore-Merion-Wynnewood Patch

Restaurant: Barbacoa
Address: 64 Rittenhouse Place, Ardmore, PA 19003
Rating: ???? out of 5 stars
Style: Rotisserie and barbecue
Food: Slow-cooked meats and home style sides
Atmosphere: Neighborhood casual
Service: Attentive
Price Range: Dinner sandwiches: $6.95 to $9.95, or $11.95 to $13.99 for a pound of meat
Parking: On-street parking

It is a safe assumption to make that we will thoroughly enjoy dining at a place that greets us with a decorative metal chicken. That is why we knew as we were walking up to the small patio outside of Barbacoa in Ardmore, that we were in for a good time.

As we stepped inside the small dining space, we were encouraged to find that all but one of the tables was full. We quickly grabbed the last seats in the house and began to stare at the giant chalkboard menu.

Our server appeared,?taking our drink order, then leaving us for a minute to peruse our options. This is when we noticed a little too late that Barbacoa is BYOB?something we will definitely make note of for our future visits.

By the time our server returned, we had decided to try a little of everything. Our order was comprised of a ? pound of beef brisket ($7.95),? ? pound of pulled pork ($6.95), and the filet mignon sandwich with caramelized onions on a Sarcone roll ($9.95).

We upgraded the brisket to a meal by adding ? a pound of coleslaw and potato wedges for $3.95. We also elected, as per server recommendation, a ? pound portion of Bianco mac?& cheese ($3.49), and ? pound of creamed spinach ($3.95).

While waiting for the meal to arrive, the team of servers was quite attentive, refilling our drinks regularly. This could have been because the heat from the kitchen was trying to sneak into the dining room?which would make it?feel like we were actually in Peru. We learned that Barbacoa is currently working on an air conditioning system, but?for the meantime they do a fine job of keeping the room ventilated and cool with a fan cross-breeze.

The filet mignon sandwich was delivered as a starter.? An impressive first bite led to the discovery of beautifully flavored meat. The desirable texture of the toasted Sarcone roll gave this sandwich a fantastic crunch.

Both the brisket and the pork came over grilled slices of Texas toast. The restaurant's signature barbecue sauce was generously slathered atop both of these dishes. We liked the balance of sweet and vinegar in the sauce. Either the beef or pork dishes could be made a staple in a dining-out regimen with their juicy and tender strands.

The potato wedges were exactly that?a wedge of potato hacked off with a skillful knife and deep-fried to golden perfection. The coleslaw wasn't cloyingly sweet, and even though it did have a sweetness, the vinegar highlights were the pallet-pleasers.

We made room to squeeze in some bites of creamed spinach?rich and delicious, not overly salty. Interestingly, the chef used penne instead of elbows or a smaller pasta to make the mac?& cheese. This gave a great surface area to be coated by the yummy, gooey sauce and we loved it.

It would be impossible to?finish the gigantic meal that we had ordered, so we boxed up some of the goodness to eat the next day. We also had hopes of feeding our tribe at home and knew the leftovers wouldn't cut it. So, we ordered a rotisserie chicken ($11.95) with a few sides of cornbread ($0.99 a piece) to take with us.

The chicken came with two sauces?one mustard-based, and one kind of spicy chimichurri (oil and herb) sauce. This meat was once again really tender, and even our picky 8-year-old kept tearing more pieces off to add to her plate.

We found Barbacoa's food represented a straight-ahead barbecue with Peruvian influence. If you want really good comfort food, grab a growler of beer and head on over for dinner. Barbacoa is located at 64 Rittenhouse Place and opens at 5 p.m. Monday through Saturday, 4 p.m. on Sundays.

Source: http://ardmore.patch.com/articles/restaurant-review-barbacoa

art basel 2011 straight no chaser straight no chaser bcs standings bcs standings douglas fir jim boeheim

Ceftaroline Fosamil ? Comprehensive patent search | Market ...

This report covers:

Ceftaroline Fosamil indications:? Treatment of commuity aquired pneumonia; Treatment of acute bacterial and skin structure infections
Ceftaroline Fosamil innovator: Takeda (Teflaro); Cerexa (Teflaro); Forest Labs (Teflaro)

Eliminate unnecessary risk with the industry benchmark in comprehensive patent information.Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which not only identifies relevant patents, but delivers categorisation and interpretation, all delivered by a convenient online interface. Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait. Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information.Pipeline Developer features:

Comprehensive patent searching, covering the world?s key territories (see ?search coverage? below)
Identifies patents covering molecule, formulation, process, use, combination and assay techniques? (see ?Patent Categories Identified?below)
Patent identification, categorisation and interpretation
Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims
Manual filtration of patents not relevant to generic development
Updated on a monthly basis, including changes to patent families, statuses, and litigation
Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers

Patent Categories Identified: 1. Molecular Form?a) Molecule Patents?b) Salts, Hydrates & Solvates?c) Polymorphic Forms?d) Other Molecular Forms2. Active Ingredient Preparation?a) Intermediates & Preparation Thereof?b) Final Synthetic Stages?c) Complete Synthesis?d) Purification Methods?e) Fermentation Methods?f) Biotechnology3. Formulations & Methods Thereof?a) General Formulations & Methods?b) Injectable Formulations?c) Oral Formulations?d) Other Administration-Specific Formulations?e) Excipients, Kits & Packaging4. Related Medical Use & Administration?a) New Use Related to Main Indication?b) Dosing Regimen/Administration Conditions5. Active Ingredient Combinations?a) Novel Combinations?b) Use of Combinations?c) Dosing Regimen & Administration Conditions for Combinations6. Analytical Methods?a) Assaying Methods?b) Methods of Determining Patient SuitabilitySearch coverage:Clicking on a patent family displays detailed information on the ?Core? and ?Non-Core? ?Patent Family Equivalents?. ?Core Patent Family Equivalents? are equivalent patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. Statuses are also monitored and updated. ?Extended Patent Family Equivalents? are equivalent patents found through the INPADOC database, increasing the search coverage to 70 countries.?Patent and national register access:Clicking on a listed patent/application number or text or image link will launch a pop-up window containing an image of the patent, enabling easy analysis of the patent documents. Clicking on a register link launches a pop-up window with the patent office register extract for that patent. This allows investigation into the examination status of a pending patent, opposition of a granted patent and/or payment of maintenance fees. Please note that no extra charges apply to accessing or downloading documents of any kind.Litigation alerts:Informing you of developments in court, litigation alerts can also be accessed by clicking on the litigation symbol next to the status, with links to judgements where available.Updating:To take the time and hassle out of monitoring and updating a large number of patents, all Pipeline Developer reporting is updated on a monthly basis. Convenient change flags identify new patent families, new patent family members, changes in statuses and litigation alerts. Legal status and transaction history:You can also find legal status and transaction history for ?Extended Patent Family Equivalents? by clicking on the INPADOC Family/Legal Status button for 65 additional territories.Reporting and access:All data can be exported into Microsoft Excel and print friendly versions for ease of data manipulation and reporting. Company details are confidential and all data is SSL secure. Five users per company are permitted and access levels are controlled by a nominated ?company administrator?.

Original Post Ceftaroline Fosamil ? Comprehensive patent search source Researchmoz Market Research
Ceftaroline Fosamil Reports

Source: http://www.healthcarestoreonline.com/wiki/ceftaroline-fosamil-comprehensive-patent-search

this means war bobby brown suzanne somers colbert colbert report legionnaires disease underwear bomber

Emma Watson Denies 'Fifty Shades of Grey' Rumors